文献速递消化道肿瘤放疗放疗物理与技术

NRG Oncology RTOG 0848 中放射治疗质量保证的分析

Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2023-08-19

NRG/RTOG 0848 是一项两步随机试验,评估胰头腺癌切除术后辅助化疗后加用同步氟嘧啶类化疗与放疗(第二步)的获益,对每位接受放疗的患者实施实时质量保证。2014 至 2018 年第二步随机分组共入组 354 例,其中 160 例接受放疗并纳入质量保证分析。结果显示 33% 的患者治疗计划至少需重新提交 1 次,需重新提交者中 87% 仅需 1 次,三维适形放疗患者重新提交比例为 43%,调强放疗为 31%,最常见原因是术前大体肿瘤体积(60.7%)和胰空肠吻合(47.5%)勾画存在不可接受的偏差。

要点

  • 33% 接受放疗的患者治疗计划至少需重新提交 1 次以符合方案要求。
  • 需重新提交者中 87% 仅需 1 次重新提交。
  • 三维适形放疗计划重新提交比例为 43%,调强放疗为 31%。

核心结论

  • 三分之一患者需重新提交治疗计划才能达到方案依从标准,表明在评估放疗的试验中持续投入资源开展实时、放疗前质量保证仍有必要,尤其在胰腺癌。
  • 严格的放疗质量保证对涉及放疗的临床试验至关重要,可确保评估放疗的真实效应。
  • 放疗质量保证还通过专家向执业放射肿瘤科医生反馈最佳实践,起到教育过程的作用。

研究设计与样本

  • NRG/RTOG 0848 是一项两步随机试验,评估胰头腺癌切除术后辅助化疗后加用同步氟嘧啶类化疗与放疗(第二步)的获益。
  • 对每位接受放疗的患者实施实时质量保证,由 2 名放射肿瘤学研究主席之一独立审阅每份计划。
  • 方案除基于网络的勾画图谱外,还规定通过创建特定感兴趣区生成临床治疗体积的分步说明,计划靶体积为临床治疗体积均匀外扩 0.5 cm。
  • 存在不可接受偏差的计划被退回修改并重新提交直至获批,放疗计划最终批准后开始治疗。

主要发现

  • 2014 至 2018 年,354 例患者进入第二步随机分组,其中 160 例接受放疗并纳入质量保证分析。
  • 采用三维适形放疗计划的患者重新提交比例为 43%,采用调强放疗的患者为 31%。
  • 共有 33% 的患者治疗计划至少需要重新提交 1 次。
  • 在需要重新提交的患者中,87% 仅需 1 次重新提交。
  • 重新提交最常见的原因是术前大体肿瘤体积(60.7%)和胰空肠吻合(47.5%)存在不可接受的偏差。

关键数值与推荐

  • 计划靶体积为临床治疗体积均匀外扩 0.5 cm。
  • 存在不可接受偏差的计划须退回修改并重新提交直至获批,计划最终批准后方可开始治疗。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: NRG/Radiation Therapy Oncology Group 0848 is a 2-step randomized trial to evaluate the benefit of the addition of concurrent fluoropyrimidine and radiation therapy (RT) after adjuvant chemotherapy (second step) for patients with resected pancreatic head adenocarcinoma. Real-time quality assurance (QA) was performed on each patient who underwent RT. This analysis aims to evaluate adherence to protocol-specified contouring and treatment planning and to report the types and frequencies of deviations requiring revisions. METHODS AND MATERIALS: In addition to a web-based contouring atlas, the protocol outlined step-by-step instructions for generating the clinical treatment volume through the creation of specific regions of interest. The planning target volume was a uniform 0.5 cm clinical treatment volume expansion. One of 2 radiation oncology study chairs independently reviewed each plan. Plans with unacceptable deviations were returned for revision and resubmitted until approved. Treatment started after final approval of the RT plan. RESULTS: From 2014 to 2018, 354 patients were enrolled in the second randomization. Of these, 160 patients received RT and were included in the QA analysis. Resubmissions were more common for patients planned with 3-dimensional conformal RT (43%) than with intensity modulated RT (31%). In total, at least 1 resubmission of the treatment plan was required for 33% of patients. Among patients requiring resubmission, most only needed 1 resubmission (87%). The most common reasons for resubmission were unacceptable deviations with respect to the preoperative gross target volume (60.7%) and the pancreaticojejunostomy (47.5%). CONCLUSION: One-third of patients required resubmission to meet protocol compliance criteria, demonstrating the continued need for expending resources on real-time, pretreatment QA in trials evaluating the use of RT, particularly for pancreas cancer. Rigorous QA is critically important for clinical trials involving RT to ensure that the true effect of RT is assessed. Moreover, RT QA serves as an educational process through providing feedback from specialists to practicing radiation oncologists on best practices.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Tchelebi LT, Winter KA, Abrams RA, et al. Analysis of Radiation Therapy Quality Assurance in NRG Oncology RTOG 0848. Int J Radiat Oncol Biol Phys. 2023. PMID: 37598723. doi:10.1016/j.ijrobp.2023.08.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。